Connect with us

Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website. .

Top Stories

Pfizer cuts Norway’s COVID-19 vaccine deliveries, rollout delayed

Pfizer cuts Norway's COVID-19 vaccine deliveries, rollout delayed

OSLO (Reuters) – Pfizer has cut July deliveries of its COVID-19 vaccine to Norway by 400,000 doses, delaying the Nordic country’s vaccine rollout, the company and the Norwegian Institute of Public Health (FHI) told Reuters on Thursday.

The news was first reported by Norwegian daily VG, citing Pfizer’s Norwegian arm, and Geir Bukholm, Director of Infection Prevention and Control at the Norwegian Institute of Public Health.

Pfizer, a major provider of vaccines to Norway which has dropped Astrazeneca’s jab and only offering J&J’s Jenssen vaccine under certain conditions, will now provide 800,000 doses in July, from the earlier estimated 1.2 million doses, Pfizer Norway confirmed to Reuters.

As a consequence, Norway’s vaccination programme will be delayed by one to two weeks compared to its earlier estimate, FHI said.

Prime Minister Erna Solberg said on May 12 the government aimed to offer a first dose to all those aged 18 and over by July 25.

(Reporting by Victoria Klesty; Editing by Alistair Bell)

Global Banking & Finance Review

 

Why waste money on news and opinions when you can access them for free?

Take advantage of our newsletter subscription and stay informed on the go!


By submitting this form, you are consenting to receive marketing emails from: Global Banking & Finance Review │ Banking │ Finance │ Technology. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

Recent Post